

# DEPOSITARY RECEIPTS

June 14, 2017

## NEW DR ANNOUNCEMENT

### Immuron Limited

Immuron is a product development biopharmaceutical company focused on the research and development of bovine-colostrum enriched with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. The Company continues to develop its NASH, ASH and Clostridium difficile products. The Company's reportable segments include Research and Development, which is attributable to the Company's research and development projects performed in Australia and Israel; as well as HyperImmune Products, which is attributable to Travelan activities which occur in Australia, New Zealand and Canada.

<b>DR Name:</b>	Immuron
<b>Effective Date:</b>	June 14, 2017
<b>Country of Incorporation:</b>	Australia
<b>Exchange:</b>	NASDAQ Stock Market
<b>Type of ADR Program:</b>	Sponsored - Level III
<b>Ticker Symbol:</b>	IMRN
<b>CUSIP Number:</b>	45254U101
<b>Ratio (DR:ORD):</b>	1 : 40
<b>Underlying Share Description:</b>	Ordinary
<b>Industry Classification:</b>	Pharma. & Biotech.
<b>Custodian(s) :</b>	HSBC Bank Australia Limited

To learn more about ADRs and issuer programs, please call our marketing desks:

#### New York

Ravi Davis / Rick Maehr  
DR Broker Liaison  
adrdesk@bnymellon.com  
+1 212 815 2267

#### London

Jacek Jankowski  
DR Broker Liaison  
jacek.jankowski@bnymellon.com  
+44 207 163 7427

Depository Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon and are subject to investment risks including possible loss of principal amount invested.

This announcement and the information contained herein is provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this information. We provide no advice or recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. An offering is made by means of a prospectus only. BNY Mellon is regulated by the FSA.